$5.48
+0.05(0.92%)
Mkt Cap $285M
$2.98
$7.15
52-Week Range
At a Glance
AI-generated6-K
Inventiva S.A. reported 2025 full year revenues of €4.5 million, a net loss of €354.1 million, cash runway to mid-Q1 2027, and NATiV3 Phase 3 topline results expected Q4 2026.$285M
Market Cap
$18M
Revenue
-$340M
Net Income
Employees114
Fundamentals
How The Business Makes Money
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Industry Biotechnology
Activity
Company Profile
CIK0001756594
ISINUS46124U1079
CUSIP46124U107
Phone33 3 80 44 75 00
Address50 rue de Dijon, Daix, 21121, FR
SEC EDGAR